ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017
Belatacept-Resistant Rejection Is Associated With CD28
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Trial
- mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.Transplantation · 2020Trial
- CTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients.Transplantation direct · 2026Article
- Review
- Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Outcomes of belatacept-based quadruple immunosuppression therapy in kidney transplant recipients with persistent alloimmune response: a single-center observational study.Frontiers in immunology · 2026Observational
- CO-STIMULATORY BLOCKADE PREVENTS INTRAGRAFT ACCRUAL OF CLASS-SWITCHED, ACTIVATED B CELLS DESPITE FAILING TO PREVENT T-CELL MEDIATED REJECTION.bioRxiv : the preprint server for biology · 2025Article
- One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients.Kidney international reports · 2025Article
- IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.Nature communications · 2024Article
- Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future.Kidney international reports · 2023Review
- Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality.The Journal of clinical investigation · 2023Article
- Article
- Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor-Intolerant Patients.Kidney international reports · 2023Article
- Applications of Transcriptomics in the Research of Antibody-Mediated Rejection in Kidney Transplantation: Progress and Perspectives.Organogenesis · 2022Article
- Malnutrition and immune cell subsets in children undergoing kidney transplantation.Pediatric transplantation · 2022Article
- Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.Frontiers in immunology · 2022Review
- Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion.Frontiers in immunology · 2022Article
- Biomarkers of alloimmune events in pediatric kidney transplantation.Frontiers in pediatrics · 2022Review
- Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Recently, newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent, is associated with superior patient survival and graft function compared with traditional therapy, but its adoption as a mainstay immunosuppressive therapy has been tempered by increased rejection rates. It is essential that the underlying mechanisms associated with this rejection be elucidated before belatacept is more widely used. To that end, we designed a study in a nonhuman primate kidney transplant model where animals were treated with either a belatacept- or a tacrolimus-based immunosuppressive regimen. Interestingly, we found that elevated pretransplant frequencies of CD28
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.